Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.25 Consensus Price Target from Brokerages

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) have been assigned a consensus rating of “Hold” from the six research firms that are presently covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $8.20.

A number of brokerages recently issued reports on RXRX. Morgan Stanley decreased their price objective on shares of Recursion Pharmaceuticals from $10.00 to $8.00 and set an “equal weight” rating on the stock in a research note on Thursday. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 8th. Cowen reiterated a “hold” rating on shares of Recursion Pharmaceuticals in a research report on Friday, February 28th. Finally, Leerink Partners dropped their target price on shares of Recursion Pharmaceuticals from $7.00 to $6.00 and set a “market perform” rating for the company in a report on Friday, February 28th.

Recursion Pharmaceuticals Price Performance

Shares of NASDAQ RXRX opened at $5.76 on Thursday. The stock has a market capitalization of $2.32 billion, a PE ratio of -3.76 and a beta of 1.00. Recursion Pharmaceuticals has a fifty-two week low of $3.79 and a fifty-two week high of $12.36. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The business has a fifty day moving average price of $6.83 and a two-hundred day moving average price of $6.84.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The firm had revenue of $4.60 million for the quarter, compared to the consensus estimate of $19.04 million. During the same period in the prior year, the company earned ($0.42) EPS. The company’s revenue for the quarter was down 57.8% compared to the same quarter last year. As a group, equities analysts predict that Recursion Pharmaceuticals will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Recursion Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Green Alpha Advisors LLC increased its stake in shares of Recursion Pharmaceuticals by 166.4% in the first quarter. Green Alpha Advisors LLC now owns 178,873 shares of the company’s stock valued at $946,000 after buying an additional 111,728 shares during the period. Rhumbline Advisers raised its stake in shares of Recursion Pharmaceuticals by 7.5% during the first quarter. Rhumbline Advisers now owns 359,175 shares of the company’s stock valued at $1,900,000 after acquiring an additional 25,143 shares during the last quarter. GAMMA Investing LLC lifted its holdings in shares of Recursion Pharmaceuticals by 635.2% during the first quarter. GAMMA Investing LLC now owns 38,215 shares of the company’s stock worth $202,000 after purchasing an additional 33,017 shares during the period. Wellington Management Group LLP increased its holdings in Recursion Pharmaceuticals by 9.5% in the fourth quarter. Wellington Management Group LLP now owns 114,945 shares of the company’s stock valued at $777,000 after purchasing an additional 9,927 shares during the period. Finally, California State Teachers Retirement System raised its position in Recursion Pharmaceuticals by 30.7% during the 4th quarter. California State Teachers Retirement System now owns 231,535 shares of the company’s stock worth $1,565,000 after purchasing an additional 54,449 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.